Overview QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors Status: Not yet recruiting Trial end date: 2023-12-30 Target enrollment: Participant gender: Summary To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients with advanced malignancies. Phase: Phase 1 Details Lead Sponsor: Qilu Pharmaceutical Co., Ltd.